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A B S T R A C T
Background
Acute cough due to upper respiratory tract infection (URTI) is a common symptom. Non-prescription over-the-counter (OTC)
medicines are frequently recommended as a first-line treatment, but there is little evidence as to whether these drugs are effective.
Objectives
To assess the effects of oral OTC cough preparations for acute cough.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2010, issue 1), MEDLINE
(January 1966 to March, week 2, 2010), EMBASE (January 1974 to March 2010) and the UK Department of Health National
Research Register (March 2010).
Selection criteria
Randomised controlled trials (RCTs) comparing oral OTC cough preparations with placebo in children and adults suffering from acute
cough in ambulatory settings. We considered all cough outcomes and secondary outcomes of interest were adverse effects.
Data collection and analysis
Two review authors independently screened potentially relevant citations, extracted data and assessed study quality. We performed
quantitative analysis where appropriate.
Main results
Twenty-six trials (18 in adults, eight in children) involving 4037 people (3421 adults and 616 children) were included.
In the adult studies six trials compared antitussives with placebo and had variable results. Two trials compared the expectorant guaifenesin
with placebo; one indicated significant benefit whereas the other did not. One trial found that a mucolytic reduced cough frequency and
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symptom scores. Two studies examined antihistamine-decongestant combinations and found conflicting results. Four studies compared
other combinations of drugs with placebo and indicated some benefit in reducing cough symptoms. Three trials found antihistamines
were no more effective than placebo in relieving cough symptoms.
In the children studies antitussives (two studies), antihistamines (two studies), antihistamine decongestants (two studies) and antitussive/
bronchodilator combinations (one study) were no more effective than placebo. No studies using expectorants met our inclusion criteria.
The results of one trial favoured active treatment with mucolytics over placebo. One trial tested two paediatric cough syrups and both
preparations showed a ’satisfactory response’ in 46% and 56% of children compared to 21% of children in the placebo group.
Authors’ conclusions
There is no good evidence for or against the effectiveness of OTC medicines in acute cough. The results of this review have to be
interpreted with caution due to differences in study characteristics and quality. Studies often showed conflicting results with uncertainty
regarding clinical relevance. Higher quality evidence is needed to determine the effectiveness of self-care treatments for acute cough.
P L A I N L A N G U A G E S U M M A R Y
Over-the-counter (OTC) medications for acute cough in children and adults in ambulatory settings
Acute cough is a common and troublesome symptom in people who suffer from acute upper respiratory tract infection (URTI). Many
people self-prescribe over-the-counter (OTC) cough preparations and health practitioners often recommend their use for the initial
treatment of cough. The results of this review suggest that there is no good evidence for or against the effectiveness of OTCmedications
in acute cough. The results of this review have to be interpreted with caution because the number of studies in each category of cough
preparations was small. Many studies were of low quality and very different from each other, making evaluation of overall efficacy
difficult.
B A C K G R O U N D
Description of the condition
Acute cough due to upper respiratory tract infection (URTI) is
one of the most common symptoms worldwide. A large number
of people self-prescribe non-prescription over-the-counter (OTC)
coughmedicines for themselves or their children, andmany health
professionals in primary care settings recommend them to their
patients as a first-line treatment (PAGB 2000).OTCmedicines are
available to the public from pharmacies, chemists and shops with-
outmedical or dental prescription inmost countries, as opposed to
prescription only medicines (POM). A national telephone survey
of medication use in the US indicated that in a given week, 10%
of children are given an OTC cough preparation by their carers
(Vernacchio 2008). Numerous OTC cough preparations are avail-
able but evidence regarding their efficacy is inconclusive. Some
studies of cough preparations have been shown to reduce cough
symptoms, whereas others found no effect compared with placebo
(Banderali 1995; Freestone 1997; Kurth 1978; Smith 1993).
Description of the intervention
Many studies have involved patients from different populations
that have included participants with chronic cough due to under-
lying disease such as asthma or chronic obstructive pulmonary dis-
ease or were carried out on healthy volunteers in whom cough had
been induced by chemical irritants (Gastpar 1984; Irwin 1993;
Smith 1993). Other randomised controlled trials (RCTs) com-
pared active agents and did not include a placebo. Cough prepara-
tions may contain different drugs with a variety of modes of action
which can make them difficult to compare (Morice 1998).
How the intervention might work
Non-prescription oral OTC medicines for cough have different
modes of action based on their active ingredients as follows.
1. Antitussives, for example centrally acting opioid derivatives
(Irwin 1993) or other peripherally active agents, act by reducing
the cough reflex.
2. Expectorants, i.e. drugs leading to increased bronchial
mucous production, make secretions easier to remove by cough
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or ciliary transport (Ziment 1976).
3. Mucolytics, i.e. drugs aiming to decrease the viscosity of
bronchial secretions, act to make secretions easier to clear
through coughing (Reynolds 1993).
4. Antihistamine-decongestant combinations, i.e. drugs that
are combined antihistamine H1-receptor antagonists and alpha-
adrenoceptor agonists, act by causing vasoconstriction of
mucosal blood vessels thus reducing congestion (Morice 1998).
5. Other drug combinations, i.e. fixed drug combinations
using different ingredients, have mechanisms of action based on
individual ingredients.
6. Antihistamines, i.e. antihistamine H1-receptor agonists, act
by reducing histamine release and thus reducing local congestion
and production of secretions.
Why it is important to do this review
Recent systematic reviews of OTC cough and cold preparations
revealed that there is insufficient evidence for or against an effect
of OTC cough preparations compared to placebo (Anonymous
1999; Smith 1993). However, these reviews did either not use
a systematic search for RCTs (Anonymous 1999) or performed
searches that were limited to the MEDLINE database (Smith
1993). By using a more extensive search strategy, this systematic
review aims to answer the question of whether OTC medications
used for the treatment of acute cough associated with URTI are
effective.
O B J E C T I V E S
The main objective of this review was to assess the effects of oral
OTC preparations for acute cough (less than three weeks’ dura-
tion) in children and adults in ambulatory settings. Because many
different groups of OTC medicines are available, we aimed to
make comparisons only within groups of preparations with a sim-
ilar mode of action or other similar features.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All placebo-controlled RCTs of oral OTC cough preparations for
acute cough.
Types of participants
1. Ambulatory settings in primary care and hospital
outpatients.
2. Children and adults with acute onset of cough (less than
three weeks’ duration).
Studies testing OTC medicines for chronic cough (more than
three weeks’ duration), cough due to underlying respiratory disease
(such as asthma, chronic obstructive pulmonary disease, pneumo-
nia, tuberculosis, lung malignancy) were excluded. We also ex-
cluded studies where cough was induced artificially (through in-
halation of chemicals) in healthy volunteers.
Types of interventions
Non-prescription oral OTC medicines for cough are classified ac-
cording to their mode of action as outlined above and we have
grouped them as follows.
1. Antitussives, for example, centrally acting opioid
derivatives.
2. Expectorants, i.e. drugs leading to increased bronchial
mucous production (Ziment 1976).
3. Mucolytics, i.e. drugs aiming to decrease the viscosity of
bronchial secretions (Reynolds 1993).
4. Antihistamine-decongestant combinations, i.e. drugs that
are combined antihistamine H1-receptor antagonists and alpha-
adrenoceptor agonists which cause vasoconstriction of mucosal
blood vessels (Morice 1998).
5. Other drug combinations, i.e. fixed drug combinations
using different ingredients.
6. Antihistamines, i.e. antihistamine H1-receptor agonists.
We excluded studies that used non-oral preparations (for example,
nasal sprays, inhalers, nebulised solutions) or that tested ingredi-
ents other than those accepted in Western (allopathic) medicine
(for example, herbal or homeopathic medicines) because we felt
that this review would have become too broad.
Types of outcome measures
Primary outcomes
All cough outcomes (such as frequency, severity, amount of spu-
tum, improvement in cough symptoms using continuous and cat-
egorical data and different ways of measurement including cough
sound pressure levels, cough counts, patient questionnaires, physi-
cian assessment, etc). We did not consider global patient or physi-
cian ratings of wellness or recovery as outcomes, unless these were
directly related to cough symptoms.
Secondary outcomes
Significant adverse effects.
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Search methods for identification of studies
Electronic searches
This reviewwas first published in 2001.We searched theCochrane
Controlled Trials Register (The Cochrane Library, 2000, issue 2),
MEDLINE (January 1998 to December 1999), EMBASE (Jan-
uary 1998 to December 1999) and the UKDepartment of Health
National Research Register (December 2000).
For the 2004 review update, we searched the Cochrane Central
Register of Controlled Trials (CENTRAL) (The Cochrane Library,
2004, issue 2), MEDLINE (January 1966 to June Week 3, 2004),
EMBASE (January 1990 toMarch 2004) and theUKDepartment
of Health National Research Register (December 2003).
For the 2007 review update we searched the Cochrane Central
Register of Controlled Trials (CENTRAL) (The Cochrane Library
2006, issue 4), MEDLINE (January 1966 to January Week 1,
2007), EMBASE (January 1990 to January 2007) and the UK
Department of Health National Research Register (June 2007,
http://www.update-software.com/National/nrr-frame.html).
For this 2010 update we searched theCochraneCentral Register of
Controlled Trials (CENTRAL) (The Cochrane Library 2010, issue
1),MEDLINE (January 1966 toMarch, week 2, 2010), EMBASE
(January 1974 toMarch 2010) and the UKDepartment of Health
National Research Register (March 2010).
We used the following search strategy to search MEDLINE
and CENTRAL. We combined the MEDLINE search with the
Cochrane Highly Sensitive Search Strategy for identifying ran-
domised trials in MEDLINE: sensitivity- and precision max-
imising version (2008 revision) Ovid format (Lefebrve 2008).
The search string was modified slightly to search EMBASE (see
Appendix 1).
MEDLINE (OVID)
1 exp COUGH/
2 cough$.mp.
3 or/1-2
4 exp Antitussive Agents/
5 exp expectorants/
6 exp Cholinergic antagonists/
7 exp Histamine H1 Antagonists/
8 exp Drug Combinations/
9 exp Drugs, Non-Prescription/
10 exp Self medication/
11 (antituss$ or expectorant$ or anticholinerg$ or antihistamin$
or (cough adj suppress$) ormucolytic$ or (drug adj combination$)
or over-the-counter or OTC or non prescription).mp.
12 or/4-11
13 3 AND 12
Searching other resources
We searched personal collections of references and reference lists
of articles and wrote to authors of original studies, pharmaceutical
companies and the Proprietary Association of Great Britain about
information on unpublished studies. There were no constraints
based on language or publication status.
Data collection and analysis
Selection of studies
Two review authors (SS, TF) independently screened potentially
relevant citations and applied the selection criteria using an in/
out/pending sheet. Any differences at any stage of the review were
resolved by discussion.
Data extraction and management
Two review authors (SS, TF) independently extracted data and
assessed the quality of studies. We contacted investigators for ad-
ditional information if necessary and obtained translations of ab-
stracts or papers if they were written in languages other than En-
glish or German.
Assessment of risk of bias in included studies
For the 2010 update of this review we adapted our original qual-
ity assessment using the new ’Risk of bias’ tool outlined in the
Cochrane Handbook for Systematic Reviews of Interventions to as-
sess the methodological quality of included studies. These as-
sessments were carried out independently by two review authors
(SS, TF). The elements considered are now described within the
Characteristics of included studies table. They included the fol-
lowing
1. Adequate sequence generation?
2. Allocation concealment?
3. Blinding?
4. Incomplete outcome data addressed?
5. Free of selective reporting?
6. Free of other bias?
Measures of treatment effect
Because of the small numbers of trials in each category, the limited
quantitative data available and themarked differences between tri-
als in terms of participants, interventions and outcome measure-
ment we felt that pooling of the results was inappropriate and no
meta-analysis was undertaken. The effect of individual treatments
is summarised as outlined in the original studies using mean dif-
ferences in scores for continuous data or simple comparison of
proportions for dichotomous data.
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Unit of analysis issues
All included studies were RCTs with randomisation occurring at
the level of individual participants so there was no indication to
consider unit of analysis errors in this review.
Dealing with missing data
Due to the limited quantitative data available for this review,
simple descriptions of individual study outcomes were presented
within the pre-specified grouping of different treatment groups.
Issues relating to missing data and follow up are presented in the
Risk of bias sections in the Characteristics of included studies ta-
ble.
Assessment of heterogeneity
The studies included in this review were clinically heterogeneous
and provided limited data so no meta-analysis was undertaken.
Assessment of reporting biases
There is no reason to suspect that publication bias affected the
outcomes of this review. We conducted a comprehensive search
of the literature with no language or publication restrictions. For
the original review information was also sought from experts in
the area including pharmaceutical companies and the Proprietary
Association of Great Britain and Ireland. As no meta-analysis was
performed we did not generate funnel plots.
Data synthesis
No meta-analysis was undertaken for this review.
Subgroup analysis and investigation of heterogeneity
Effects of treatment are presentedwithin relevant treatment groups
for both children and adults to allow comparison of related med-
ications.
Sensitivity analysis
Nometa-analysis was undertaken and limitations of the review are
addressed within the Discussion section.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
Our initial search in 2001 identified 328 potentially relevant RCTs
which we screened for retrieval of paper copies. At that stage we
excluded 235 abstracts for the followingmain single reasons: study
not an RCT (n = 19 trials); study not placebo controlled (n =
39); study not testing an OTC cough medicine (n = 86); cough
artificially induced (n = 26); or participants with chronic cough
lasting more than three weeks (n = 65). Paper copies of 93 RCTs
were retrieved for more detailed evaluation. We excluded a further
72 trials because studies were not RCTs (n = 4); were not placebo
controlled (n = 2); were not testing OTC cough medicines (n =
23); induced cough artificially (n = 3); included participants with
chronic cough (n = 25); or did not report any cough outcomes (n
= 15).
The search conducted for the update in 2004 identified three
additional RCTs, with two of these being different arms of a three-
arm RCT (Korppi 1991a; Korppi 1991b; Pavesi 2001).
The search conducted for the update in 2007 identified one addi-
tional RCT (Paul 2004) and the search conducted for this 2010
update identified one additional RCT (Mizoguchi 2007).
Included studies
In this 2010 update we included 26 RCTs involving 4037 par-
ticipants. Eighteen of these trials were in adults (n = 3421) and
eight in children (n = 616). The Characteristics of included studies
table contains data on the number of participants randomised to
the interventions, age, sex, smoking status, study setting, defini-
tion of illness, drug dosage, frequency and duration of treatment,
and outcome information. Most adult trials were on young adults
with mean ages ranging from 23 to 48 years. Ages in studies on
children ranged from six months to 18 years. Six trials were more
than 20 years old. Half the studies (12 out of 26) were carried out
in the USA, with the remaining trials located in the UK (five),
Finland (three), Germany (two), Italy (one), India (one), South
Africa (one) and Thailand (one). The ages of participants ranged
from six months to over 70 years. Most studies were different in
their definition of illness, the content of the drug preparation,
drug dosage, the frequency of doses and the treatment duration
(ranging from a single dose to 18 days), making comparison of
trials and quantitative analysis difficult.
Excluded studies
The commonest reasons for excluding studies were that cough
was artificially induced or lasted longer than three weeks or cough
outcomeswere not clearly reported. SeeCharacteristics of excluded
studies table.
Risk of bias in included studies
5Over-the-counter (OTC) medications for acute cough in children and adults in ambulatory settings (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Allocation
Most studies did not report sufficient details on randomisation and
allocation schedules to make meaningful conclusions about the
potential for selection bias. Only four of the 26 trial reports stated
the randomisation process which was adequate in three trials.
Loss to follow up was well documented in 17 studies with differ-
ential loss to follow up in the treatment arms reported in five stud-
ies, with the potential for attrition bias difficult to assess for the
remaining studies. Only one of the studies fulfilled all the quality
criteria. Only six trials reported a power calculation.
Blinding
In seven studies the outcome assessors were blinded to treatment
allocation and six studies did not report whether participants and/
or treatment providers were blinded with a potential for detection
and performance bias.
Incomplete outcome data
Because a number of studies dated back many years, it was often
impossible to obtain additional trial data. Because the reporting of
potential causes of biaswas poor inmany trials, we did not formally
examine the trial efficacy versus the trial quality and therefore only
summarised the available data in the ’Risk of bias’ section of the
Characteristics of included studies. These contain summary data
on randomisation processes used, blinding to treatment allocation,
drop-outs/losses to follow up and any additional comments.
Other potential sources of bias
Eleven of the 26 included studies (Adams 1993; Berkowitz 1991;
Gaffey 1988; Mizoguchi 2007; Parvez 1996; Pavesi 2001; Reece
1966; Robinson 1977; Sakchainanont 1990; Thackray 1978;
Tukiainen 1986) were fully or partly supported by pharmaceuti-
cal companies which provided grants, supplied the drugs in ques-
tion or gave assistance with the study. Eight out of the 11 studies
supported by the pharmaceutical industry showed positive results
compared to three out of 15 trials where no support was reported.
Effects of interventions
We grouped the trials according to drug class into antitussives,
expectorants, mucolytics, antihistamine-decongestant combina-
tions, other combinations and antihistamines. The number of
studies in each group ranged fromone to amaximumof six.Cough
outcomes included frequency, severity and night-time symptoms
and were measured in many different ways, for example, partici-
pant self-report by symptom scores (interviews, questionnaires, di-
aries), physician assessment, observation by parents, cough sound
pressure levels obtained by recordings via a microphone and tape
recordings. Seventeen studies out of 26 reported data on adverse
effects and five studies reported data on compliance with medi-
cation. Eleven out of the 26 trials reported quantitative data for
the cough that could potentially have been used for meta-analy-
sis. Because of the small numbers of trials in each category, the
limited quantitative data available and the marked differences be-
tween trials in terms of participants, interventions and outcome
measurement we felt that pooling of the results was inappropriate.
1. Antitussives
1.1 Studies in adults
We included six trials involving 1526 participants that compared
antitussives with placebo.
Codeine was tested in two trials and appeared no more effective
than placebo in reducing cough symptoms (Eccles 1992; Freestone
1997). One of these studies (n = 81) tested codeine in a two-phase
study (laboratory and home) at a dose of 30 mg four times daily
for four days (Eccles 1992) and codeine was no more effective
than placebo either as a single dose or in a total daily dose of
120 mg, reported on a five-point cough severity score (P > 0.2).
The second study (n = 82) of codeine only tested the effect of
a single 50 mg dose (Freestone 1997) and cough was assessed
via microphone using cough sound pressure levels 90 minutes
after drug administration, cough frequency counts and subjective
scores. The mean subjective score on a five-point rating scale was
reduced from 2.0 to 1.0 90 minutes after treatment (P = 0.8) in
both treatment groups. Both studies did not provide any data on
side effects.
Dextromethorphanwas tested in three of the included studies (Lee
2000; Parvez 1996; Pavesi 2001). One report on a series of three
successive studies on a total of 451 adults (Parvez 1996) favoured
dextromethorphan 30 mg given in a single dose to placebo in
terms of cough counts (measured through cough acoustic signals
using a microphone on the nose) and subjective visual analogue
scales.Differences inmean changes of cough counts between active
treatment and placebo varied from 19% to 36% (P < 0.05) in the
three studies (up to a net difference of eight to 10 coughing bouts
every 30 minutes). This study did not report on side effects.
A recent study of dextromethorphan tested a single 30 mg dose
versus placebo (Lee 2000). Both treatment groups showed a de-
cline in cough frequency (from 50 to 19 per 10-minute period in
the active treatment arm compared with 42 to 20.5 in the placebo
arm, P = 0.38 at 180 minutes follow up). Mean subjective cough
scores showed a decline from 2.0 to 1.0 in the active treatment
group compared to a decline from 2.0 to 1.5 in the placebo group
(P = 0.08).
Pavesi and colleagues also tested a single 30 mg dose of dex-
tromethorphan versus placebo (Pavesi 2001). Outcomes were
measured through a three-hour continuous cough recording, mea-
suring cough bouts, cough components, cough effort, cough in-
tensity and cough latency. Average treatment difference was 12%
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to 17% in favour of dextromethorphan for cough bouts (P =
0.004), cough components (P = 0.003) and cough effort (P =
0.001) with an increase in cough latency (P = 0.002).
One trial on 108 adults (Adams 1993) comparing moguisteine at
a total daily dose of 600 mg for three and a half days with placebo
showed no difference apart from cough reduction in individuals
with more severe night cough (mean score difference of about
0.5 on a scale from 0 to 9, P < 0.05 using Bonferroni correction
for multiple comparisons). There were more side effects in the
treatment group (22%) compared to placebo (8%) which mainly
included nausea, vomiting and abdominal pain. There were four
withdrawals in the treatment group due to adverse effects.
1.2 Studies in children
One study involving 57 children with night cough compared a
single dose for three nights of dextromethorphan and codeine
with placebo (Taylor 1993). Mean cough and composite scores
decreased in each of the three treatment groups on each day of the
study. Neither dextromethorphan (cough score reduction of 2.1,
P = 0.41) nor codeine (cough score reduction of 2.2, P = 0.70)
was more effective than placebo (cough score reduction of 2.2) on
day three.
Another study involving 50 children compared dextromethorphan
1.5mg perml 5ml three times a day for children under seven years
and 10ml three times daily for older children (Korppi 1991a) with
placebo. There were no differences between the groups in terms
of parent-recorded symptom scores or adverse effects, which were
generally mild.
A third study involving 100 children compared a single nocturnal
dose of dextromethorphan (dose based on child’s age: age two to
five, 7.5 mg; age six to 11, 15 mg; age 12 to 18, 30 mg with either
a single dose of an antihistamine or with placebo) (Paul 2004).
Dextromethorphan was no more effective than diphenhydramine
or placebo in reducing cough frequency or impact on child or
parental sleep.
2. Expectorants
2.1 Studies in adults
Two trials with a total of 304 participants compared guaifenesin
with placebo (Kuhn 1982; Robinson 1977). In the larger study
(n = 239), 75% of participants taking guaifenesin stated that the
medicine was helpful in terms of reducing cough frequency and
intensity compared to 31% in the control group (P < 0.01) at
72 hours (Robinson 1977). Four participants (two in each group)
reported side effects including nausea and hives in the active treat-
ment group and headaches, drowsiness and excessive perspiration
in the placebo group.
The second study (n = 65) evaluated an antitussive rather than
expectorant effect of guaifenesin, which is usually classified as an
expectorant (Kuhn 1982). Individuals in both groups reported
improvement with respect to cough frequency (100% in the active
group versus 94% for placebo, P = 0.5) and cough severity (100%
in the active treatment group versus 91% in the placebo group, P
= 0.2) at 36 hours. Guaifenesin reduced sputum thickness signif-
icantly in 96% of participants compared to 54% in the placebo
group (P = 0.001). This study allowed aspirin and paracetamol for
participants after inclusion in the study, and the vehicle contained
95% alcohol. Adverse effects were not reported on.
2.2 Studies in children
Wedidnot include any studies that tested expectorants in children,
partly because none of the outcomes under study were reported
on.
3. Mucolytics
3.1. Studies in adults
One trial involving 99 participants compared bromhexine 5
mg three times daily for an average of four days with placebo
(Nesswetha 1967). Frequent cough (every two to five minutes)
was more prevalent in the placebo group (15.2%) compared to
active treatment (8.6%, P < 0.02) leading to a risk ratio reduction
of about 50% for frequent cough. This study did not report on
any adverse effects.
3.2 Studies in children
One trial involving 40 children compared themucolytic letosteine
(preparation not available in the UK and other parts of the world)
at a dose of 25 mg three times daily for 10 days with placebo
(Nespoli 1989). The symptom score on a four-point scale favoured
active treatment from day four until day 10 with an average dif-
ference of about 0.2 points (P < 0.01). No adverse effects were
reported in either group.
4. Antihistamine-decongestant combinations
4.1 Studies in adults
Two trials on adults with a total of 356 participants com-
pared antihistamine-decongestant combinations with placebo
(Berkowitz 1989; Curley 1988). One trial comparing loratadine/
pseudoephedrine (5 mg/120 mg twice daily for four days) with
placebo (n = 283) did not show statistically significant differences
in cough scores reported in patient diaries between both groups
(Berkowitz 1989). Thirty percent of participants in the active
treatment group reported adverse effects including dry mouth,
headache and insomnia compared to 21% in the control group.
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The second trial (n = 73) compared dexbrompheniramine/pseu-
doephedrine (6mg/120mg twice daily for oneweek)with placebo.
The mean severity rank of cough on a scale from zero to four
obtained through a patient diary was less in the active treatment
group (1.4) than in the placebo group (2.0) on days three to five (P
< 0.05) (Curley 1988). There was an increased severity of dizziness
and dry mouth in the active drug group on days 5 to 7, and 2 to
10, respectively (exact figures not reported, P = or < 0.01).
4.2 Studies in children
Two studies involving 155 children compared antihistamine-de-
congestant combinations with placebo (Clemens 1997; Hutton
1991). Brompheniramine/phenylpropanolamine (2 mg/12.5 mg,
half the dose for children from six months to one year, on a four-
hourly ’as needed’ basis for 48 hours) was no more effective than
placebo in reducing the number of children coughing two hours
after each dose (49.0% versus 43.1%, P = 0.66). A higher propor-
tion of children was reported asleep in the active treatment group
(46.6%) than in the placebo group (26.5%, P = 0.53), and no
other adverse effects were reported (Clemens 1997).
In the second study (n = 96), a combination of brompheniramine/
phenylephrine/propanolamine (see Characteristics of included
studies table for full dosage details) led to a not statistically sig-
nificant improvement in cough in 67% of children (reported by
their parents) compared to 58% in the placebo group and 70%
in the group receiving no treatment (Hutton 1991). Side effects
were rare and included one child with loose stools in the placebo
group and one child reported hyperactive in the active drug group.
A second child in the drug group was reported sleepier than usual.
5. Other drug combinations
For the constituent ingredients of the drug combination formula-
tions included in the review please refer to the Characteristics of
included studies table.
5.1 Studies in adults
Four studies involving 836 people compared other combinations
with placebo (Kurth 1978; Thackray 1978; Tukiainen 1986).
These studies were very heterogeneous and used very different
drug preparations and dose frequency, limiting their comparabil-
ity.
In one trial (n = 113) EM-VIER (Minetten) given six times daily
was more effective in reducing coughing fits (25% versus 11%,
P < 0.01) and the urge to cough (27% versus 14%, P < 0.01)
compared to placebo in the first seven days (Kurth 1978). There
were no adverse effects in either group.
In a trial of Vicks Medinite syrup (n = 70) at a single dose at bed-
time for two days, 57.6% of participants in the active treatment
group rated the formulation as “good” or better in relieving cough
compared to 32.2% in the placebo group (P < 0.01) (Thackray
1978). Seven subjects in the active treatment group reported gid-
diness/drowsiness compared to four subjects in the placebo group.
Another study (n = 108) compared a dextromethorphan/salbu-
tamol combination and dextromethorphan alone with placebo
(Tukiainen 1986). There was spontaneous improvement of cough
in all groups, and there were no statistically significant differences
in cough scores between active treatments and placebo for both
cough frequency and severity during the day. Dextromethorphan/
salbutamol was superior to placebo or dextromethorphan alone in
relieving cough at night (mean symptom score 0.19 versus 0.67
and 0.44, respectively on day four, P < 0.01). The dextromethor-
phan/salbutamol combination led to more tremor than placebo
(no figures given, P < 0.05), and no serious adverse effects were
reported.
A further study (n = 545), identified for the 2009 update of this re-
view, compared a single nocturnal dose of a compound containing
four agents eachwith potential to deal with the different symptoms
of the common cold, i.e. paracetamol plus dextromethorphan plus
doxylamine plus ephedrine (Mizoguchi 2007).We only report the
cough-related outcomes. The outcomes in this study were mea-
sured over the following two days and included proportions who
reported improvements in cough three hours after taking the treat-
ment and mean cough scores on day 1 and day 2. There was a
significant improvement in mean cough score the morning after
treatment and the following day (mean cough score 2.5 versus 2.08
on day 2, P < 0.0001). There were also improvements in the pro-
portion reporting improvement in cough three hours after taking
the medication (intervention 57% and control 43%). There were
19 adverse events in the study in 14 patients with no difference
between treatment and control. However, there was one serious
adverse event described as a severe episode of somnolence in the
active treatment group.
5.2 Studies in children
One trial involving 43 children tested two paediatric cough syrups
(Triaminicol syrup and Dorcol paediatric cough syrup) (Reece
1966). Compared to placebo, 69% of children in both active treat-
ment groups showed a satisfactory response reported by their par-
ents compared to 57% of children in the placebo group which did
not reach statistical significance (P = 0.5). Adverse effects were not
reported.
One RCT in 51 children compared a combination of dex-
tromethorphan 1.5 mg per ml and salbutamol 0.2 mg per ml 5
ml three times daily for children under the age of seven or 10 ml
three times a day for older children (Korppi 1991b) with placebo.
There were no differences between the groups in terms of parent-
recorded symptom scores or adverse effects, which were generally
mild.
6. Antihistamines
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6.1 Studies in adults
Three trials involving 1900 adult participants compared antihis-
tamines with placebo (Berkowitz 1991;Gaffey1988;MRC1950).
Antihistamines were no more effective than placebo in relieving
cough symptoms. Terfenadine was tested in two studies. In one
of these studies (n = 100), terfenadine at a dose of 120 mg twice
daily for four to five days led to a mean cough score (measured
by physicians’ evaluation on a scale from zero to three with higher
scores meaning more coughing) of 0.8 in the active treatment
group compared to 0.65 in the placebo group, a difference which
was not statistically significant (P = 0.35) (Berkowitz 1991). Pos-
sible adverse effects were rare in both groups, with headache being
the most common complaint (6.1% of participants in the active
treatment group compared to 4% in the placebo group).
The second study (n = 250) tested terfenadine at a dose of 60 mg
twice daily for three and a half days (Gaffey 1988). There were
no statistically significant differences in self-reported symptoms
scores for cough (exact figures not reported) between groups. Side
effects were uncommon in both treatment groups, with the most
common complaint being excess fatigue in 12% of subjects receiv-
ing terfenadine compared to 10% in the placebo group.
Thonzylamine at a dose of 50 mg three times a day for three days
led to an improvement or cure of cough in 61.8% of subjects in
the active treatment group compared to 59.8% in the placebo
groupwhichwas not statistically significant (P =0.5) (MRC 1950).
Adverse effects were reported by 20.9% of individuals in the active
treatment group compared to 19.2% in the placebo group, with
the most common complaints being drowsiness, giddiness and
headache.
6.2 Studies in children
Two trials involving 243 children compared antihistamines with
placebo. One compared the antihistamines clemastine (0.05 mg/
kg/day) and chlorpheniramine (0.35 mg/kg/day) for three days
with placebo (Sakchainanont 1990). There was spontaneous im-
provement in all groups. In both active treatment groups, cough
scores observed by physicians and participants improved in 39.6%
of individuals compared with 27.6% in the placebo group which
did not reach statistical significance (P = 0.2). Drowsiness and
sleepiness were reported in 20% of children with no difference
between the groups. The second trial included an arm in which
children received diphenhydramine in a single nocturnal dose
and were compared with children receiving placebo (Paul 2004).
Diphenhydramine was no more effective than dextromethorphan
or placebo in reducing cough frequency or impact on child or
parental sleep.
D I S C U S S I O N
Most studies failed to provide quantitative data on cough as our
main outcome of interest, which made it very difficult to assess
whether positive study resultswere clinically relevant.Quantitative
data that could be combined showed wide confidence intervals,
although there was no evidence of statistical heterogeneity. Many
included studies failed to report adverse effects adequately and
patient compliance with the treatment was not discussed in the
vast majority of study reports. Three studies carried out multiple
comparisons, thereby increasing the probability of a type I error
(Berkowitz 1989; Parvez 1996; Pavesi 2001). A number of studies
were supported by pharmaceutical companies, whereas the others
failed to report their sources of funding or any conflict of interest.
Summary of main results
We found no good evidence for or against the effectiveness ofOTC
medications in acute cough which confirms the findings of two
previous reviews (Anonymous 1999; Smith 1993). The number
of trials in each group of drugs was small, there was poor overall
quality of the studies, and studies showed conflicting evidence. In
total, 11 of the 26 included trials showed a positive result, whereas
15 did not show active treatment to be superior to placebo. Eight
out of the 11 studies that were supported by the pharmaceutical
industry showed positive results compared to three positive studies
out of the 15 trials that did not report any conflict of interest. The
results of trials did not appear to be related to their sample size or
length of follow up. We did not formally examine the trial efficacy
versus trial quality because of the lack of reported data.
Overall completeness and applicability of
evidence
The results of this systematic review have to be interpreted with
caution as the number of trials in each group was small. There
were marked differences between the studies even within groups
of drugs with similar mode of action, making it difficult to com-
pare trials directly. In addition, there is variation between coun-
tries in relation to medications available over the counter, making
international comparisons more difficult. Inclusion and exclusion
criteria for participants varied, and active drugs were administered
in different total daily doses. The duration of drug therapy varied
from a single-dose treatment to an 18-day course. For example,
six studies testing antitussives either alone or in combination with
other agents, used short-term cough relief after a single dose as
an outcome (Freestone 1997; Lee 2000; Mizoguchi 2007; Parvez
1996; Paul 2004; Pavesi 2001), whereas more relevant outcomes
for patients would be the effect after one day, three days or a week.
Outcomes were assessed and measured in many different ways
which included questionnaires, cough severity scores, acoustic sig-
nals, tape recordings, daily diaries and assessment by a physician.
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Most studies failed to provide quantitative data on cough as our
main outcome of interest, which made it very difficult to assess
whether positive study resultswere clinically relevant.Quantitative
data that could be combined showed wide confidence intervals,
although there was no evidence of statistical heterogeneity. Many
included studies failed to report adverse effects adequately, and
patient compliance with the treatment was not discussed in the
vast majority of study reports. Three studies carried out multiple
comparisons, thereby increasing the probability of a type I error
(Berkowitz 1989; Parvez 1996; Pavesi 2001). A number of studies
were supported by pharmaceutical companies, whereas the others
failed to report their sources of funding or any conflict of interest.
Quality of the evidence
The overall quality of trials is dubious and there are conflicting
results between trials in each medication group. The method of
outcome measurement and the resulting magnitude of effect were
unclear or not very well reported in some studies.
Potential biases in the review process
Eleven of the 26 included studies were funded by the pharmaceu-
tical industry as outlined in the ’Risk of bias’ section in the Re-
sults. Studies funded in this way weremore likely to report positive
results. However, despite this potential bias the review does not
provide evidence of the effectiveness of OTC cough medicines for
acute cough.
Agreements and disagreements with other
studies or reviews
The findings of this review and other related published evidence
were considered by an expert panel of the US Food and Drug
in October 2007 and there was consensus that there is limited
evidence to support the recommendation to use OTC cough
medicines for acute cough in children (FDA 2007). The review
findings are also supported by a recent non-Cochrane systematic
review which found few studies that examined the effectiveness of
diphenhydramine for acute cough despite its widespread use and
these studies indicated limited clinical effectiveness (Bjornsdottir
2001).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is no good evidence for or against the effectiveness of OTC
cough medicines and from the studies included in this review it re-
mains unclear whether these medications are helpful for the treat-
ment of acute cough. Although a number of RCTs have compared
OTC cough preparations with placebo, the number of trials in
each group was small. This review suggests that most preparations
appear to be safe, based on those studies reporting side effects
which only described a low incidence of mainly minor adverse
effects. However, more serious concerns about the safety of OTC
cough medicines have arisen since this review was last updated,
particularly in young children and, in general, larger numbers of
patients are required to pick up serious though less common ad-
verse effects (Smith 2008a). This systematic review confirms the
lack of evidence for or against an effect ofOTCcough preparations
despite using an extensive search strategy. This lack of evidence of
effectiveness also has implications for the regulatory bodies and
brings into question how these products can continue to be pro-
moted using language that implies that their effectiveness is not
in doubt.
The results of this review have to be interpreted with caution
because study designs, populations, interventions and outcomes
varied markedly between studies, limiting the generalisability of
the results. All results were based on a small number of studies. It is
also questionable as to whether all of the positive results obtained
with unclear outcome measures are clinically relevant.
Implications for research
Further high quality RCTs of OTC cough preparations are needed
as the results of this review are based on a small number of often
underpowered studies. More evidence about the effectiveness of
OTC cough preparations would be helpful, as identification of
effective self-care treatments may help reduce the burden of days
lost at work due to acute cough as well as the number of consul-
tations in primary care. Research should also include individuals
who self-medicate with OTC cough preparations, as there is likely
to be a variation between countries in the proportion of individ-
uals using these medications, with or without professional advice,
particularly given the international variation in what products are
available OTC or on a prescription basis. There is also a need to
identify ineffective preparations in order to lower costs for con-
sumers and health care providers. Studies will need to be rigorously
designed and should use clinically relevant outcome measures, in-
cluding cough frequency, severity and duration. It is important
that future RCTs use OTC drugs in doses recommended by the
manufacturers for an appropriate length of time, as drugs tested
in a single and possibly too low a dose are likely to be ineffective.
Trials should also report details on effect sizes and provide data on
adherence and adverse effects. This review also highlights a need
for an outcome measure for acute cough that is clinically relevant,
valid, reliable and easy to use in RCTs.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Adams 1993
Methods RCT
Participants 108 adults, mean age 48 years, 70% women, 60% smokers, UK primary care, acute dry
or slightly productive cough
Interventions Antitussive: moguisteine 200 mg 3 times daily for 3.5 days
Outcomes Patient recorded cough scale from 0 to 9. Mean score difference of 0.5 between groups,
P less than 0.05
Notes More side effects in treatment group (22%) compared to placebo (8%) mainly including
nausea, vomiting and abdominal pain. Four withdrawals in the treatment group due to
adverse effects
Risk of bias
Item Authors’ judgement Description
Blinding?
All outcomes
Yes Patient and provider blinded but not outcome assessor
Incomplete outcome data addressed?
All outcomes
Yes 10% loss to follow up and reasons reported
Free of other bias? No Trial supported by pharmaceutical industry
Berkowitz 1989
Methods RCT
Participants 283 adults, mean age 30 years, mainly Caucasian, 52% women, 3 ’centres’, USA, com-
mon cold
Interventions Antihistamine-decongestant combination: loratadine 5 mg and pseudoephedrine 120
mg combination twice daily for 5 days
Outcomes Patient diaries, cough score from0 to3.No significant difference in cough score reduction
(0.8 in active treatment group versus 0.6 in the placebo group, P greater than 0.05)
Notes Adverse effects (dry mouth, headache and insomnia) more common in active treatment
group (30%) compared to placebo group (21%)
Risk of bias
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Berkowitz 1989 (Continued)
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer-generated
Blinding?
All outcomes
Yes
Incomplete outcome data addressed?
All outcomes
Yes Overall 92% follow up and similar in both groups
Free of other bias? Unclear Many multiple comparisons made
Berkowitz 1991
Methods RCT
Participants 100 adults, mean age 32, 56% women, non-smokers, single centre (setting not reported)
, USA, common cold
Interventions Antihistamine: terfenadine 120 mg twice daily for 4 to 5 days
Outcomes Patient diary and symptom score from 0 to 3. No statistically significant difference
between cough scores in active treatment group (0.81, standard error 0.13) and placebo
(0.61, standard error 0.12), P = 0.35
Notes Possible adverse effects rare in both groups. Headache most common (6.1% in active
treatment group versus 4% in placebo group)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Reported as “randomly assigned”
Blinding?
All outcomes
Unclear Blinding assumed but not clearly stated
Incomplete outcome data addressed?
All outcomes
Yes Overall 96% follow up and similar in both groups
Free of other bias? No Trial supported by pharmaceutical industry
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Clemens 1997
Methods RCT
Participants 59 pre-school children, mean age 2 years (6 months to 5 years), 4 paediatric offices, USA, URTI
of less than 7 days’ duration
Interventions Antihistamine-decongestant combination: brompheniramine maleate 2 mg/5 ml and phenyl-
propanolamine-hydrochloride 12.5 mg/5 ml (6 months to 1 year: 1.5 teaspoon and 2 to 5 years: 1
teaspoon) every 4 hours “as needed” for 48 hours
Outcomes Parent questionnaire, 7-point Likert scale, also counted ’responses’ after each dose. Mean cough
scores 4.67 (active treatment) versus 4.57 (placebo), P = 0.53
Notes Higher proportion of children asleep in the active treatment group (46.6%) versus placebo (26.
5%)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Reported as patients “randomly assigned in a double blind fashion”
Blinding?
All outcomes
Yes Patients, providers and outcome assessor blinded, patient blinding unclear
Curley 1988
Methods RCT
Participants 73 adults, mean age 31 years, 60% women, 19% active smokers, outpatient department,
USA, common cold of less than 72 hours duration
Interventions Antihistamine-decongestant combination: dexbrompheniramine maleate 6 mg and
pseudoephedrine sulphate 120 mg combination twice daily for 1 week
Outcomes Patient diary and cough score from 0 to 4. Mean severity cough score 1.4 (active) versus
2.0 (placebo), P less than 0.05 on days 3 to 5
Notes Increased severity of dizziness and dry mouth in the active drug group compared to
placebo (P equal or less than 0.01, exact figures not reported)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer-generated
Blinding?
All outcomes
Yes Patients and providers blinded; outcome assessor blinding not
reported
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Curley 1988 (Continued)
Incomplete outcome data addressed?
All outcomes
Yes 85% follow up, difference between groups not reported. Overall
drop-outs due to inconvenience of study and not due to side
effects
Eccles 1992
Methods RCT
Participants 81 adults, mean age 23 years (range 18 to 71), 52% men, hospital research clinic, UK,
cough associated with URTI
Interventions Antitussive: codeine linctus 30 mg/10 ml 4 times daily for 4 days
Outcomes Cough severity score (5-point scale) from diaries expressed as area under the curve for 8
measures over 5 days. Mean cough scores 18.8 (placebo) versus 17.2 (codeine), P = 0.23
Notes No data on adverse effects provided
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes
Blinding?
All outcomes
Yes Patients and providers blinded; outcome assessor blinding not
reported
Incomplete outcome data addressed?
All outcomes
Yes 90% follow up; no reporting of differences between groups
Freestone 1997
Methods RCT
Participants 82 university students and staff, mean age 24 years (range 18 to 46), 62%men, ’common
cold centre’, university department, UK, cough associated with URTI
Interventions Antitussive: codeine phosphate 50 mg as a single dose
Outcomes Five-point subjective rating scale, cough sound pressure levels, cough frequency. Mean
score reductions from 2.0 to 1.0 in both treatment groups (P = 0.8). Also no significant
differences for cough sound pressure levels and cough frequency
Notes No data on adverse effects reported
Risk of bias
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Freestone 1997 (Continued)
Item Authors’ judgement Description
Blinding?
All outcomes
Yes Patients and providers blinded; outcome assessor blinding not
reported
Incomplete outcome data addressed?
All outcomes
Unclear Follow up not reported
Free of other bias? Unclear No power calculation reported
Gaffey 1988
Methods RCT
Participants 250 adults, mean age 23 years, 65% women, internal medicine clinic, USA, common
cold
Interventions Antihistamine: terfenadine 60 mg twice daily for 3.5 days
Outcomes Patient diary and symptom score from zero to three. Symptom scores for cough ”virtually
the same in the terfenadine and placebo recipients”, but no exact scores reported
Notes Side effects uncommon in both groups, with the most common complaint being excess
fatigue (12% in active versus 10% in placebo group)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Reported as “subjects received sequential admission numbers
and were randomly assigned”
Blinding?
All outcomes
Unclear Blinding presumed but not clearly reported
Incomplete outcome data addressed?
All outcomes
Yes 94% follow up; difference between groups not reported. Non-
compliers were considered to be drop-outs
Free of other bias? No Participants were “compensated for participation”
Trial supported by pharmaceutical industry
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Hutton 1991
Methods RCT
Participants 96 inner-city African-American children, 6 months to 5 years, mean age about 2 years,
primary care clinic, USA, symptoms of URTI
Interventions Antihistamine-decongestant combination: brompheniramine maleate 4 mg/5 ml,
phenylephrine 5 mg/5 ml, propanolamine 5 mg/5 ml (doses calculated to achieve
brompheniramine dosage of 0.5 to 0.75 mg/kg/d) 3 times daily for 2 days
Outcomes Nine-point symptom score by parents or physician, follow-up telephone interviews.
“Improvement” reported in 20/30 (67%) in the active treatment group compared to 14/
24 (58%) in the placebo group and 21/30 (70%) in the group receiving no treatment
(P = 0.5 and 0.8, respectively)
Notes Side effects were rare including one child with loose stools in the placebo group and one
child reported as hyperactive in the active treatment group. A second child in the drug
group was reported sleepier than usual
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes
Blinding?
All outcomes
Yes
Incomplete outcome data addressed?
All outcomes
Yes Follow up 86% in active treatment group and 89% in placebo
group
Korppi 1991a
Methods RCT
Participants Arm of 3-arm RCT, 50 children with respiratory infection, private paediatric practices,
mean age 3.8 years, 53% boys, Finland
Interventions Antitussive: dextromethorphan 1.5 mg per ml 5 ml 3 times daily for children under 7
years and 10 ml 3 times daily for older children
Outcomes Daily symptom score recorded by parents including cough frequency and severity on a
scale from 0 to 3. Scores dropped in both groups with no difference between groups
Notes Small study with no power calculation reported. Low incidence of adverse effects with
no differences between groups
Risk of bias
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Korppi 1991a (Continued)
Item Authors’ judgement Description
Adequate sequence generation? Unclear Reported as “randomly divided” into treatment groups
Allocation concealment? Unclear Not reported
Blinding?
All outcomes
Yes Reported as double-blind; outcome assessor blinding not re-
ported
Incomplete outcome data addressed?
All outcomes
Yes Follow up 96%
Korppi 1991b
Methods RCT
Participants Arm of 3-arm RCT, 51 children with respiratory infection, private paediatric practices, mean age 3.8
years, 53% boys, Finland
Interventions Other combination: dextromethorphan 1.5 mg per ml and salbutamol 0.2 mg per ml 5 ml 3 times daily
for children under 7 years and 10 ml 3 times daily for older children
Outcomes Daily symptom score recorded by parents including cough frequency and severity on a scale from 0 to 3.
Scores dropped in both groups with no difference between groups
Notes Small study with no power calculation reported. Low incidence of adverse effects with no differences
between groups
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear D - Not used
Kuhn 1982
Methods RCT
Participants 65 adults (mostly university students), age range 18 to 30 years, university research
centre, USA, URTI with cough for less than 48 hours
Interventions Mucolytic: expectorant: guaifenesin 480 mg/30 ml every 6 hours for 30 hours
Outcomes Tape recordings of cough frequency, questionnaire on 6 symptoms. Cough frequency:
33/33 (100%) improved in the active treatment group versus 30/32 (94%) in the placebo
group, P = 0.5. Cough severity: improved in 33/33 (100%) in the active treatment group
versus 29/32 (91%) in the placebo group, P = 0.2
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Kuhn 1982 (Continued)
Notes Study did not report on adverse effects
Risk of bias
Item Authors’ judgement Description
Blinding?
All outcomes
Yes Patients and providers blinded; outcome assessor blinding not
reported
Incomplete outcome data addressed?
All outcomes
Yes No losses to follow up
Free of other bias? Unclear No power calculation reported
Kurth 1978
Methods RCT
Participants 113 adults, 57% men, age range from under 30 to over 70 years (no details given),
primary care, Germany, cough due to URTI
Interventions Other combination: EM-Vier Minetten: Extr thymi aquos.sicc 5 mg, succus liquiritiae
depurat. inspiss. 20 mg, menthol 3.5 mg, ephedrine hydrochloric 2 mg, ol. eucalypti 2
mg, ol. menthae piperitae 0.7 mg 6 times daily for 14 to 18 days
Outcomes Outcome measurement unclear. 26/58 (44.8%) in the active treatment group improved
within the first 3 days compared to 15/55 (27.3%) in the placebo group, P = 0.05
Notes No adverse effects in either group
Risk of bias
Item Authors’ judgement Description
Blinding?
All outcomes
Yes Patients blinded; blinding of providers and outcome assessors
not reported
Incomplete outcome data addressed?
All outcomes
Unclear 95% follow up. No difference between groups
Free of other bias? Unclear No power calculation reported
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Lee 2000
Methods RCT
Participants 44 adults from 18 to 60 years (mean age 23 years), 70% women, university staff and
students and general city population, UK
Interventions Antitussive: dextromethorphan 30 mg as a single dose
Outcomes Cough frequency recordings, cough sound pressure levels, questionnaire on cough sever-
ity (scale from 0 to 3). Decline in cough frequency of 31.0 (active) versus 21.5 (placebo)
, P = 0.38. Mean decline in cough score 1.0 (active) versus 0.5 (placebo), P = 0.08
Notes Side effects not reported
Risk of bias
Item Authors’ judgement Description
Blinding?
All outcomes
Yes Patients and providers blinded; outcome assessor blinding not
reported
Incomplete outcome data addressed?
All outcomes
Unclear 98% follow up; remaining 2% reported as being due to lack of
motivation to participate in the study
Free of other bias? Unclear Only retrospective power calculation reported
Mizoguchi 2007
Methods RCT
Participants 485 adult volunteers with URTI with cough, for greater than 1 day and less than 5 days,
aged 18 to 65 attending 10 study centres in the USA
Interventions Single 30 ml dose of a test syrup containing 15 mg dextromethorphan; 7.5 mg doxycy-
cline; 8 mg ephedrine and 600 mg paracetamol
Outcomes Mean cough score on day 1 and day 2 following active treatment: active treatment 2.5
versus placebo 2.08 on day 2
% with improved cough 3 hours following active treatment: 57% improved in active
treatment group compared with 43% in placebo group
Adverse events: 5/224 in treatment group (1 serious event described as a severe episode
of somnolence) and 9/208 in control group
Notes Other outcomes relating to URTI were also presented but we included only cough-
related outcomes
Risk of bias
Item Authors’ judgement Description
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Mizoguchi 2007 (Continued)
Adequate sequence generation? Yes Subjects stratified by sex and overall symptom severity score and
block randomised
Allocation concealment? Yes
Blinding?
All outcomes
Yes Patients and providers blinded; outcome assessor blinding not
reported
Incomplete outcome data addressed?
All outcomes
Yes Overall 89% completed full follow up, 79% had per protocol
analysis, minimal imbalance between groups
Free of other bias? No Interim power calculation carried out during study by indepen-
dent external statistician
Trial supported by pharmaceutical industry
Nespoli 1989
Methods RCT
Participants 40 children, age range 2 to 12 years (median 7.5 years), paediatric clinic, Italy, acute febrile bronchitis
Interventions Mucolytic: letosteine 25 mg 3 times daily for 10 days
Outcomes Cough score from 0 to 3, unclear how this was measured. Lower cough scores in the active treatment
group compared to placebo (difference between groups ranging from 0.1 to 0.3 points from day 4 to 10,
P less than 0.01)
Notes No adverse effects reported in both groups
Risk of bias
Item Authors’ judgement Description
Blinding?
All outcomes
Yes
Free of other bias? Unclear Interim power calculation carried out during study by independent external statis-
tician
Nesswetha 1967
Methods RCT
Participants 99 factory workers in the chemical industry, age range 15 to 44 years, Germany, URTI
Interventions Mucolytic: bisolvon linctus (N-cyclohexyl-N-methyl-(2-amino-3,5-dibrombenzyl) am-
monium chloride 4 mg in 5 ml 3 times daily for an average of 4 days
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Nesswetha 1967 (Continued)
Outcomes Outcome measurement not clearly described, used 4-point scale. Frequent cough (de-
fined as cough every 2 to 4 minutes) present in 4/46 (8.6%) in the active treatment
group versus 7/46 (15.2%) in the placebo group (P less than 0.02)
Notes Study did not report on adverse effects
Risk of bias
Item Authors’ judgement Description
Blinding?
All outcomes
Yes Patients and providers blinded; outcome assessor blinding not
reported
Incomplete outcome data addressed?
All outcomes
Yes 93% follow up; difference between groups not reported
Free of other bias? Unclear No power calculation reported
Parvez 1996
Methods RCT
Participants 451 adults in 3 different studies, mean age 30 years, 65% men, mainly non-smokers,
corporate health centre, India, URTI
Interventions Antitussive: dextromethorphan 30 mg as a single dose
Outcomes Cough acoustic signals captured via microphone over 180 minutes. Differences in mean
changes between cough counts varied from 19 to 36 per cent (P less than 0.05) in the 3
studies (up to a net difference of 8 to 10 coughing bouts every 30 minutes)
Notes This study did not report on adverse effects
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Minimisation using a computer program
Blinding?
All outcomes
Yes Patients and providers blinded; outcome assessor blinding not
reported
Incomplete outcome data addressed?
All outcomes
Unclear Not reported but drop outs unlikely due to short period of follow
up
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Parvez 1996 (Continued)
Free of other bias? No Many multiple comparisons with no corrections and high prob-
ability of type I error
Trial supported by pharmaceutical industry
Paul 2004
Methods RCT
Participants 100 children (age range 2 to 18 years), cough due toURTI, university affiliated paediatric
practices in USA
Interventions Antitussive: dextromethorphan as single dose based on age
Antihistamine: diphenhydramine as single dose 1.25 mg/kg
Outcomes Cough frequency score on 7-point scale
Sleep disturbance in children and their parents
Notes Adverse effects:
13/33 in dextromethorphan arm
9/33 in diphenhydramine arm
9/33 in placebo group
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes
Blinding?
All outcomes
Yes Patients and providers blinded; outcome assessor blinding not
reported
Incomplete outcome data addressed?
All outcomes
Yes No losses to follow up
Pavesi 2001
Methods Meta-analysis of 5 RCTs
Participants 710 adults in 5 different studies, mean age 30 years, 50% women, 90% non-smokers, settings ’clinics’ and
’in-home’ studies, South Africa and India, uncomplicated upper respiratory infection
Interventions Antitussive: dextromethorphan 30 mg as a single dose
Outcomes Three-hour continuous cough recording, measuring cough bouts, cough components, cough effort, cough
intensity and cough latency. Average treatment difference 12% to 17% in favour of dextromethorphan in
cough bouts (P = 0.004), cough components (P = 0.003) and cough effort (P = 0.001) with an increase in
cough latency (P = 0.002)
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Pavesi 2001 (Continued)
Notes Study funded and conducted by pharmaceutical company. Results poorly reported
Risk of bias
Item Authors’ judgement Description
Blinding?
All outcomes
Yes
Free of other bias? No No power calculation reported. Medication sponsored by medical director of
a laboratory who also performed the analysis
Reece 1966
Methods RCT
Participants 43 children, mean age 3.6 years (range 2 months to 12 years), 58 % boys, ambulatory
private practice, USA, cough due to URTI
Interventions Other combination: dextromethorphan, guaifenesin and pseudoephedrine (Triamini-
col syrup) and dextromethorphan, guaifenesin and pseudoephedrine (Dorcol paediatric
cough syrup), treatment frequency and duration unclear
Outcomes Parent assessment. ’Satisfactory’ response in 11/16 (69%) and 9/13 (69%) in the inter-
vention groups compared to 8/14 (57%) in the placebo group, P = 0.5 for both com-
parisons (responses and P values were calculated from the percentages)
Notes Adverse effects were not reported
Risk of bias
Item Authors’ judgement Description
Blinding?
All outcomes
Yes Patients blinded; blinding of providers and outcome assessors
not reported
Incomplete outcome data addressed?
All outcomes
Unclear Follow up not reported
Free of other bias? No No power calculation reported. Medication sponsored by med-
ical director of a laboratory who also performed the analysis
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Robinson 1977
Methods RCT
Participants 239 adults, mean age about 38 years, smokers and non-smokers evenly distributed, office
or clinic outpatients, USA, acute URTI
Interventions Expectorant: guaifenesin 200 mg/10 ml 4 times daily for 3 days
Outcomes Patient questionnaires, cough scores from 0 to 3. 79/105 (75%) in the active treatment
group found theMEDLINE helpful compared with 33/106 (31%) in the placebo group,
P less than 0.01
Notes Two participants in each group reported side effects including nausea and hives in the ac-
tive treatment group and headaches, drowsiness and excessive perspiration in the placebo
group
Risk of bias
Item Authors’ judgement Description
Blinding?
All outcomes
Yes
Incomplete outcome data addressed?
All outcomes
Yes 89% follow up; no difference between groups
Free of other bias? No No power calculation reported
Trial supported by pharmaceutical industry
Sakchainanont 1990
Methods RCT
Participants 143 children under 5 years, mean age 23 months (range 1.5 to 60 months), 50% girls,
paediatric out-patient department, Thailand, common cold
Interventions Antihistamine: 2 groups: clemastine fumarate (0.05 mg/kg/d twice daily) and chlor-
pheniramine maleate syrup (0.35 mg/kg/d 3 times daily) for 3 days
Outcomes Parent assessment using 4-level symptom score. Cough “improved” in 19/48 (39.6%)
in the chlorpheniramine group compared with 13/47 (27.6%) taking placebo, P = 0.2
Notes Drowsiness and sleepiness reported in 20% of children with no difference between the
treatment groups
Risk of bias
Item Authors’ judgement Description
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Sakchainanont 1990 (Continued)
Blinding?
All outcomes
Yes
Incomplete outcome data addressed?
All outcomes
Yes 95% follow up; no difference between groups
Free of other bias? No No power calculation reported. Bonferroni correction for mul-
tiple comparisons used
Trial supported by pharmaceutical industry
Taylor 1993
Methods RCT
Participants 57 children, mean age 4.7 years (range 18 months to 12 years), 53% boys, 82% white,
private practices, USA, night cough due to URTI
Interventions Antitussive: dextromethorphan 15 mg/5 ml and codeine 10 mg/ 5 mg as a single dose
at bed time for 3 nights
Outcomes Parent questionnaire, cough score from 0 to 4. Mean reductions in cough scores 2.2
(codeine) and 2.1 (dextromethorphan) versus 2.2 in the placebo group, P = 0.52 and 0.
97 respectively
Notes Both active treatments also contained guaifenesin 100 mg/5 ml. Adverse effects mainly
drowsiness, diarrhoea and hyperactivity: placebo 7/13 (54%), dextromethorphan 6/19
(32%, P = 0.2) and codeine 5/17 (29%, P = 0.8)
Risk of bias
Item Authors’ judgement Description
Blinding?
All outcomes
Yes Patients and providers blinded; outcome assessor blinding not
reported
Incomplete outcome data addressed?
All outcomes
Yes 86% follow up; difference between groups not reported
Free of other bias? Unclear Post hoc power calculation demonstrates that studywas powered
to detect a difference of 0.9 in cough score which is equivalent to
natural resolution of cough at day 3. Authors argue that smaller
reductions in cough scores are unlikely to be clinically important
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Thackray 1978
Methods RCT
Participants 70 adults, mean age 34 years (range 18 to 60), 61% women, 21 general practices, UK,
common cold
Interventions Other combination: Vicks Medinite syrup (dextromethorphan 15 mg, ephedrine 600
mg, doxylamine 7.5 mg, paracetamol 600 mg per dose) single dose at bedtime for 2 days
Outcomes Questionnaire, 6-point rating scale. Cross-over design: 34/59 (57.6%) of subjects rated
active treatment good or better compared to 19/59 (32.2%) in the control group, P less
than 0.01
Notes Seven subjects in the active treatment group reported giddiness/drowsiness compared to
4 subjects in the placebo group
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear “Patients allotted by a random number code”
Blinding?
All outcomes
Unclear Patients and providers blinded; outcome assessor blinding not
reported
Incomplete outcome data addressed?
All outcomes
Yes No losses to follow up
Free of other bias? No Main investigator was medical director of the company supply-
ing the drug for the study. Cross-over after 1 day, no washout
period
Tukiainen 1986
Methods RCT
Participants 108 outpatients, mean age about 38 years, 55% women, 48% smokers, Finland, cough
associated with URTI
Interventions Other combination: dextromethorphan (30 mg) alone and in combination with salbu-
tamol (2 mg) 3 times daily for 4 days
Outcomes Patient diary and symptom score from 0 to 3. No statistically significant differences
between mean treatment scores for daytime cough on day 4 1.26 (dextromethorphan
plus salbutamol), 1.28 (dextromethorphan) and 1.15 (placebo), no exact P value given.
Dextromethorphan/salbutamol was more effective in suppressing cough at night com-
pared to plain dextromethorphan (0.45 +/- 0.10 versus 0.92 +/- 0.14, P less than 0.01)
on day 3
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Tukiainen 1986 (Continued)
Notes Dextromethorphan/salbutamol combination led tomore tremor than placebo (no figures
given, P less than 0.05), no serious adverse effects reported
Risk of bias
Item Authors’ judgement Description
Blinding?
All outcomes
Yes Patients and providers blinded, outcome assessor blinding not
reported
Incomplete outcome data addressed?
All outcomes
Unclear Follow up not reported
Free of other bias? No No power calculation reported
Trial supported by pharmaceutical industry
RCT: randomised controlled trial
URTI: upper respiratory tract infection
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Kim 2009 Abstract only published and inclusion criteria unclear. Main publication awaited
MRC 1950 Cough outcome not clearly reported
Paul 2007 No placebo control group
URTI: upper respiratory tract infection
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D A T A A N D A N A L Y S E S
This review has no analyses.
A P P E N D I C E S
Appendix 1. Embase.com search strategy
12. #8 AND #11
11. #9 OR #10
10. random*:ab,ti OR placebo*:ab,ti OR factorial*:ab,ti OR crossover*:ab,ti OR ’cross over’:ab,ti OR ’cross-over’:ab,ti OR ((doubl*
OR singl*) NEAR/2 (blind* OR mask)):ab,ti OR assign*:ab,ti OR allocat*:ab,ti OR volunteer*:ab,ti
9. ’single blind procedure’/exp OR ’double blind procedure’/exp OR ’crossover procedure’/exp OR ’randomized controlled trial’/exp
8. #3 AND #7
7. #4 OR #5 OR #6
6. ’cough suppressant’:ab,ti OR ’cough suppressants’:ab,ti OR ’drug combination’:ab,ti OR ’drug combinations’:ab,ti OR ’over the
counter’:ab,ti OR ’over-the-counter’:ab,ti OR otc:ab,ti OR ’behind the counter’:ab,ti OR ’behind-the-counter’:ab,ti OR ’non prescrip-
tion’:ab,ti OR ’non-prescription’:ab,ti OR nonprescription:ab,ti
5. antituss*:ab,ti OR expectorant*:ab,ti OR anticholinerg*:ab,ti OR antihistamin*:ab,ti OR mucolytic*:ab,ti
4. ’antitussive agent’/exp OR ’expectorant agent’/exp OR ’cholinergic receptor blocking agent’/exp OR ’histamine h1 receptor antag-
onist’/exp OR ’drug combination’/exp OR ’behind the counter drug’/exp OR ’non prescription drug’/exp OR ’self medication’/exp
3. #1 OR #2
2. cough*:ab,ti
1. ’coughing’/de OR ’irritative coughing’/de
WH A T ’ S N E W
Last assessed as up-to-date: 7 April 2010.
Date Event Description
19 March 2010 New search has been performed One study added (Mizoguchi 2007) to this update but did not lead to anymajor
changes in the conclusions of this review
H I S T O R Y
Protocol first published: Issue 4, 1999
Review first published: Issue 3, 2001
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Date Event Description
6 August 2009 Amended Contact details updated.
8 May 2009 Amended Contact details updated.
2 June 2008 Amended Converted to new review format.
4 July 2007 New search has been performed Searches conducted.
25 July 2004 New search has been performed Searches conducted.
12 December 1999 New search has been performed Searches conducted.
C O N T R I B U T I O N S O F A U T H O R S
Knut Schroeder (KS) and Tom Fahey (TF) conceived and designed the original review, undertook the searches, performed data
collection, screened the search results, screened retrieved papers against the inclusion criteria, appraised the quality of the papers,
extracted data from papers, interpreted the data, organised the retrieval of papers, wrote to authors of papers for additional information,
managed the data, entered data into Review Manager and wrote the review.
Susan Smith (SS) updated the review in 2007 and in 2010, including screening updated search results, data extraction, quality appraisal
and rewriting the review.
D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• Division of Primary Health Care, University of Bristol, UK.
External sources
• South & West Research and Development Directorate, UK.
• NHS Primary Care Career Scientist Fund, UK.
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N O T E S
A single randomised controlled trial (RCT) was added to this review in the 2007 update (Paul 2004).
Paul et al tested a single nocturnal dose of dextromethorphan, or a single nocturnal dose of diphenhydramine versus placebo. The
outcomes in this study were measured the following morning and included a cough severity index and a measure of sleep difficulty
both for the affected children and their parents. This study showed no significant treatment differences between the two intervention
groups and the control group.
Average treatment differences between 12% and 17% in favour of dextromethorphan for cough bouts (P = 0.004), cough components
(P = 0.003) and cough effort (P = 0.001) with an increase in cough latency (P = 0.002).
A further single RCT was added for the 2010 update (Mizoguchi 2007).
Mizoguchi et al compared a single nocturnal dose of a combination test syrup containing dextromethorphan, doxycycline, ephedrine
and paracetamol with placebo. The outcomes in this study were measured the over the following two days and included proportions
reporting improvements in cough three hours after taking the treatment and mean cough scores on day 1 and day 2. This study showed
significant treatment differences between the two intervention groups and the control group in terms of reduction in mean cough
scores on day 2.
The addition of these study did not lead to any major changes in the conclusions of this review.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Acute Disease; Administration, Oral; Ambulatory Care; Antitussive Agents [∗administration & dosage]; Cough [∗drug therapy]; Drug
Therapy, Combination; Expectorants [administration & dosage]; Histamine H1 Antagonists [administration & dosage]; Nonprescrip-
tion Drugs [∗administration & dosage]; Randomized Controlled Trials as Topic
MeSH check words
Adult; Child; Humans
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